ESR1 and breast carcinoma: Intriguingly, both canonical and noncanonical Wnt signaling pathways are activated in tamoxifen-resistant breast cancer cells, and Wnt3a increases the resistance of EsR+ breast cancer cells to tamoxifen treatment [384].